NCT00637481

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: National Cancer Institute (NCI) · NIH
• Sex: Female
• Age: 18 Years – 72 Years
• Healthy volunteers: Accepted

Summary

Chemoprevention is the use of certain drugs to keep cancer from forming. The use of atorvastatin (Lipitor) may prevent breast cancer. This randomized phase I trial is studying the best dose of atorvastatin in preventing breast cancer in women at increased risk for breast cancer.

Detailed description

PRIMARY OBJECTIVES: I. To determine the minimum biological effective dose (MBED) of atorvastatin required to induce modulation in the proliferation marker, Ki-67, in breast tissue of women who are at high risk to develop breast cancer. We will evaluate pre- and post atorvastatin treatment (4 dose levels) expression of Ki-67 in samples obtained via FNA from breast tissue of women at high risk for breast cancer. This specific aim tests the hypothesis that treatment with atorvastatin will induce a decrease in Ki-67. SECONDARY OBJECTIVES: I. To evaluate atorvastatin induced modulation of breast cancer biomarkers markers (EGFR, P-EGFR, ER, p21, p27, bcl-2, CC3, cytology) and drug related markers (LXR, total cholesterol, LDL, HDL, CRP) in women who are at high risk to develop breast cancer. II. To determine plasma and tissue levels of atorvastatin and two of its hydroxylated metabolites (ohydroxyatorvastatin and p-hydroxyatorvastatin) in women who are treated with atorvastatin and to correlate these levels with Ki-67 levels. III. To correlate changes in Ki-67 and the above-described panel of biomarkers with HMG-CoA reductase genotype. OUTLINE: Participants are randomized to 1 of 4 arms. ARM I: Participants receive oral atorvastatin once daily for 3 months. ARM II: Participants receive oral atorvastatin (at a higher dose than in arm I) once daily for 3 months. ARM III: Participants receive oral atorvastatin (at a higher dose than in arm II) once daily for 3 months. ARM IV: Participants do not receive treatment. Participants undergo blood sample collection and fine needle aspiration of breast tissue at baseline and at 3 months for correlative biomarker studies.

Conditions

• Atypical Ductal Breast Hyperplasia
• Breast Cancer
• Ductal Breast Carcinoma in Situ
• Lobular Breast Carcinoma in Situ

Interventions

Type	Name	Description
DRUG	atorvastatin calcium	Given orally
OTHER	laboratory biomarker analysis	Correlative studies

Timeline

• Start date: 2008-03-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2008-03-18
• Last updated: 2016-12-29

Locations

1 site across 1 country: United States